Market Research Logo

Global Intrauterine Contraceptive Device Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023

Global Intrauterine Contraceptive Device Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023

Intrauterine contraceptive device is a small T-shaped device which is inserted in the uterus of a woman in order to prevent pregnancy. The global intrauterine contraceptive device market is expected to rise at a CAGR of 10% during the forecast period 2016-2023. Intrauterine contraceptive devices are a form of long lasting reversible method for birth control. They are 99% effective in preventing unwanted pregnancy, convenient to use, are reversible and starts working immediately after installation. Due to these advantages, intrauterine contraceptive devices are used by large number of women across the world.

North America is the largest market region for intrauterine contraceptive device market owing to the increased adoption of these devices in United States. There is high rate of unplanned pregnancies among the teenagers in the U.S. Moreover, increasing number of initiatives taken by the U.S. government has helped to reduce the rising number of unplanned pregnancies and abortions rate in United States. Furthermore, many U.S. based private companies have also contributed and provided the solutions for issues during pregnancy which includes teenage pregnancies, maternal mortality, increasing number of abortions etc., by promoting the advantages and use of intrauterine contraceptive devices. Furthermore, Asia Pacific is expected to emerge as the fastest increasing market owing to the presence of leading pharmaceutical companies in Asia Pacific countries such as China, Japan, India etc.

The global intrauterine contraceptive device market is influenced by the presence of major pharmaceutical companies such as Agile therapeutics, Actavis PLC, Bayer healthcare AG, Teva pharmaceuticals industries, Johnson & Johnson etc. Product launch, joint venture, merger and acquisition are some of the crucial strategies adopted by the key market players to gain competitive advantage.

Global intrauterine contraceptive device market report covers segmentation analysis of device type and products. Report further covers segments of device type which includes hormonal intra uterine device and copper intra uterine device. Among these segments, copper intra uterine device is the leading segment due to its increased adoption as it is more convenient to use, low threats of side effects, and is considered to be safe for women. Among the females using IUD, 79% of them use Copper Intra uterine device worldwide. Report further covers segments of products such as Mirena, Skyla, Paragard, Essure, Levosert etc. Mirena is the widely used product thereby accounts for highest market growth globally . Mirena Intrauterine contraceptive device with Progestogen is extensively used to facilitate long time birth control and is 99% effective than other product segments .

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.


1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
2. MARKET OVERVIEW
2.1. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICE MARKET: EVOLUTION & TRANSITION
2.2. MARKET DEFINITION & SCOPE
2.3. INDUSTRY STRUCTURE
2.4. REGULATORY FRAMEWORK
2.5. TOTAL MARKET ANALYSIS
2.5.1. TOP 5 FINDINGS
2.5.2. TOP 5 OPPORTUNITY MARKETS
2.5.3. TOP 5 COMPANIES
2.5.4. TOP 3 COMPETITIVE STRATEGIES
2.6. ESTIMATION ANALYSIS
2.7. STRATEGIC ANALYSIS
2.7.1. INVESTMENT VS. ADOPTION MODEL
2.7.2. 360-DEGREE INDUSTRY ANALYSIS
2.7.3. PORTERS 5 FORCE MODEL
2.7.4. SEE-SAW ANALYSIS
2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.8. COMPETITIVE ANALYSIS
2.8.1. KEY STRATEGIES & ANALYSIS
2.8.2. MARKET SHARE ANALYSIS AND TOP COMPANY ANALYSIS
2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
3. MARKET DETERMINANTS
3.1. MARKET DRIVERS
3.1.1. TECHNOLOGICAL ADVANCEMENTS IN IUD
3.1.2. INCREASING RATE OF SEXUALLY TRANSMITTED DISEASES
3.1.3. PREGNANCY PREVENTION
3.1.4. IMMEDIATE HEALTH BENEFITS OTHER THAN BIRTH CONTROL
3.1.5. RISE IN GOVERNMENT INITIATIVES TO PREVENT UNWANTED ABORTIONS AND PREGNANCIES
3.2. MARKET RESTRAINTS
3.2.1. LIMITED ACCESS TO CONTRACEPTION
3.2.2. INFERTILITY ISSUES
3.2.3. ECONOMIC CONSTRAINTS
3.3. MARKET OPPORTUNITIES
3.3.1. NEW PRODUCT PIPELINES
3.3.2. SAFEST OPTION AS COMPARED TO OTHER CONTRACEPTIVE PRESENT IN THE MARKET
3.4. MARKET CHALLENGES
3.4.1. THREAT OF CAUSING PELVIC INFLAMMATORY INFECTION (PID)
3.4.2. THREAT OF CAUSING ECTOPIC PREGNANCY
4. MARKET SEGMENTATION
4.1. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICE MARKET BY TYPE
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION
4.1.5.1. GLOBAL HORMONAL INTRA UTERINE DEVICEMARKET
4.1.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.1.5.1.4. KEY CONCLUSIONS
4.1.5.2. GLOBAL COPPER INTRA UTERINE DEVICEMARKET
4.1.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.1.5.2.4. KEY CONCLUSIONS
4.2. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICE MARKET BY PRODUCTS
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION
4.2.5.1. GLOBAL MIRENAMARKET
4.2.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.1.4. KEY CONCLUSIONS
4.2.5.2. GLOBAL SKYLA MARKET
4.2.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.2.4. KEY CONCLUSIONS
4.2.5.3. GLOBAL PARAGARD MARKET
4.2.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.3.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.3.4. KEY CONCLUSIONS
4.2.5.4. GLOBAL ESSURE MARKET
4.2.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.4.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.4.4. KEY CONCLUSIONS
4.2.5.5. GLOBAL LEVOSERT MARKET
4.2.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.5.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.5.4. KEY CONCLUSIONS
4.2.5.6. GLOBAL OTHER PRODUCTS MARKET
4.2.5.6.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.6.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.6.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.6.4. KEY CONCLUSIONS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF MERGERS AND ACQUISITION
5.1.2. LIST OF JOINT VENTURES
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIPS
6. GEOGRAPHICAL ANALYSIS
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICE MARKET BY REGION 2014-2023 ($ MILLION)
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S.
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. SPAIN
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. REST OF EUROPE
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. AUSTRALIA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. REST OF ASIA PACIFIC
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
7. COMPANY PROFILES
7.1. AGILE THERAPEUTICS (U.S.)
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY INNOVATION SECTOR
7.1.4. STRATEGIC INITIATIVES
7.1.5. SCOT ANALYSIS
7.1.6. STRATEGIC ANALYSIS
7.2. ACTAVIS PLC (U.S.)
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY INNOVATION SECTOR
7.2.4. STRATEGIC INITIATIVES
7.2.5. SCOT ANALYSIS
7.2.6. STRATEGIC ANALYSIS
7.3. BAYER HEALTHCARE AG (U.S.)
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY INNOVATION SECTOR
7.3.4. STRATEGIC INITIATIVES
7.3.5. SCOT ANALYSIS
7.3.6. STRATEGIC ANALYSIS
7.4. TEVA PHARMACEUTICALS INDUSTRIES, LTD (ISRAEL)
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY INNOVATION SECTOR
7.4.4. STRATEGIC INITIATIVES
7.4.5. SCOT ANALYSIS
7.4.6. STRATEGIC ANALYSIS
7.5. JOHNSON & JOHNSON, LTD (U.S.)
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY INNOVATION SECTOR
7.5.4. STRATEGIC INITIATIVES
7.5.5. SCOT ANALYSIS
7.5.6. STRATEGIC ANALYSIS
7.6. LUPIN PHARMACEUTICALS, LTD (INDIA)
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY INNOVATION SECTOR
7.6.4. STRATEGIC INITIATIVES
7.6.5. SCOT ANALYSIS
7.6.6. STRATEGIC ANALYSIS
7.7. OKAMOTO INDUSTRIES, INC. (JAPAN)
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY INNOVATION SECTOR
7.7.4. STRATEGIC INITIATIVES
7.7.5. SCOT ANALYSIS
7.7.6. STRATEGIC ANALYSIS
7.8. PFIZER (U.S.)
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY INNOVATION SECTOR
7.8.4. STRATEGIC INITIATIVES
7.8.5. SCOT ANALYSIS
7.8.6. STRATEGIC ANALYSIS
7.9. ALLERGAN, PLC (IRELAND)
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY INNOVATION SECTOR
7.9.4. STRATEGIC INITIATIVES
7.9.5. SCOT ANALYSIS
7.9.6. STRATEGIC ANALYSIS
7.10. SMB CORPORATION (INDIA)
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY INNOVATION SECTOR
7.10.4. STRATEGIC INITIATIVES
7.10.5. SCOT ANALYSIS
7.10.6. STRATEGIC ANALYSIS
7.11. OCON MEDICAL LTD. (ISRAEL)
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. KEY INNOVATION SECTOR
7.11.4. STRATEGIC INITIATIVES
7.11.5. SCOT ANALYSIS
7.11.6. STRATEGIC ANALYSIS
7.12. MEDISAFE DISTRIBUTION, INC. (CANADA)
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. KEY INNOVATION SECTOR
7.12.4. STRATEGIC INITIATIVES
7.12.5. SCOT ANALYSIS
7.12.6. STRATEGIC ANALYSIS
7.13. MERIL LIFE SCIENCES PVT. LTD. (INDIA)
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. KEY INNOVATION SECTOR
7.13.4. STRATEGIC INITIATIVES
7.13.5. SCOT ANALYSIS
7.13.6. STRATEGIC ANALYSIS
7.14. DKT INTERNATIONAL (U.S.)
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. KEY INNOVATION SECTOR
7.14.4. STRATEGIC INITIATIVES
7.14.5. SCOT ANALYSIS
7.14.6. STRATEGIC ANALYSIS
7.15. TRIMEDIC SUPPLY NETWORK LTD (CANADA)
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. KEY INNOVATION SECTOR
7.15.4. STRATEGIC INITIATIVES
7.15.5. SCOT ANALYSIS
7.15.6. STRATEGIC ANALYSIS
LIST OF TABLES
GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICE MARKET BY TYPE ($ MILLION)
GLOBAL HORMONAL INTRA UTERINE DEVICE MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL COPPER INTRA UTERINE DEVICE MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICE MARKET BY PRODUCT ($ MILLION)
GLOBAL MIRENA MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL SKYLA MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL PARAGARD MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL ESSURE MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL LEVOSERT MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL OTHER PRODUCTS MARKET BY GEOGRAPHY ($ MILLION)
NORTH AMERICA INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
EUROPE INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
ASIA PACIFIC INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
REST OF THE WORLD INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
LIST OF FIGURES
GLOBAL INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
GLOBAL HORMONAL INTRA UTERINE DEVICE MARKET ($ MILLION)
GLOBAL COPPER INTRA UTERINE DEVICE MARKET ($ MILLION)
GLOBAL MIRENA MARKET ($ MILLION)
GLOBAL SKYLA MARKET ($ MILLION)
GLOBAL PARAGARD MARKET ($ MILLION)
GLOBAL ESSURE MARKET ($ MILLION)
GLOBAL LEVOSERT MARKET ($ MILLION)
GLOBAL OTHER PRODUCTS MARKET ($ MILLION)
UNITED STATES (U.S.) INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
CANADA INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
UNITED KINGDOM (UK) INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
FRANCE INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
GERMANY INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
SPAIN INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
ROE INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
INDIA INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
CHINA INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
JAPAN INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
AUSTRALIA INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
ROAPAC INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
LATIN AMERICA INTRAUTERINE CONTRACEPTIVE DEVICE MARKET ($ MILLION)
MENA INTRAUTERINE CONTRACEPTIVE DEVICE MARKET 2014-2023 ($ MILLION)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report